Literature DB >> 20196178

Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study.

Yuichiro Nakano1, Reiji Yoshimura, Hideki Nakano, Atsuko Ikenouchi-Sugita, Hikaru Hori, Wakako Umene-Nakano, Nobuhisa Ueda, Jun Nakamura.   

Abstract

Nitric oxide (NO) is involved in pathophysiology of psychiatric disorders such as depression and schizophrenia. We hypothesize that plasma levels of NO and its metabolites (NO(x)) are decreased in patients with schizophrenia. To examine the hypothesis, we compared plasma NO(x) levels between 30 schizophrenic patients (M/F: 18/12, age: 38 +/- 15 years) and age- and sex-matched 30 healthy controls (M/F: 18/12, age: 41 +/- 19 years), and we also examined the effects of risperidone on plasma NO(x) levels in schizophrenic patients. The baseline plasma NO(x) levels were significantly lower in the schizophrenia group (1.85 +/- 0.70 microM) than those in control group (3.37 +/- 2.27 microM). A significantly negative correlation was found between plasma NO(x) levels and PANSS-N scores before risperidone administration (rho = -0.385, p = 0.0416). Treatment with risperidone significantly increased the plasma NO(x) levels by 8 weeks (before; 1.85 +/- 0.70 microM, after; 2.25 +/- 1.00 microM, p = 0.0491). These results suggest that NO might be one of the candidates factors which are associated with the pathophysiology of negative symptoms of schizophrenia. Copyright 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20196178     DOI: 10.1002/hup.1102

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  11 in total

Review 1.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

2.  Sodium nitroprusside is effective in preventing and/or reversing the development of schizophrenia-related behaviors in an animal model: The SHR strain.

Authors:  Mariana C Diana; Fernanda F Peres; Veronica Justi; Rodrigo A Bressan; Acioly L T Lacerda; José Alexandre Crippa; Jaime E C Hallak; Vanesssa Costhek Abilio
Journal:  CNS Neurosci Ther       Date:  2018-04-14       Impact factor: 5.243

Review 3.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

4.  The nitric oxide donor sodium nitroprusside attenuates recognition memory deficits and social withdrawal produced by the NMDA receptor antagonist ketamine and induces anxiolytic-like behaviour in rats.

Authors:  Aikaterini Trevlopoulou; Ntilara Touzlatzi; Nikolaos Pitsikas
Journal:  Psychopharmacology (Berl)       Date:  2015-12-19       Impact factor: 4.530

5.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

6.  A three-month longitudinal study of changes in day/night serum total antioxidant capacity in paranoid schizophrenia.

Authors:  Armando L Morera-Fumero; Estefanía Díaz-Mesa; Pedro Abreu-Gonzalez; Lourdes Fernandez-Lopez; Fernando Guillen-Pino
Journal:  PLoS One       Date:  2017-12-08       Impact factor: 3.240

7.  Diagnostic Accuracy of Brain-derived Neurotrophic Factor and Nitric Oxide in Patients with Schizophrenia: A pilot study.

Authors:  Vladimir V Djordjević; Dušan Lazarević; Vladan Ćosić; Marinela Z Knežević; Vidosava B Djordjević; Ivana Stojanović
Journal:  J Med Biochem       Date:  2015-12-30       Impact factor: 3.402

Review 8.  Multidimensional Connectomics and Treatment-Resistant Schizophrenia: Linking Phenotypic Circuits to Targeted Therapeutics.

Authors:  Mary-Anne B MacKay; John W Paylor; James T F Wong; Ian R Winship; Glen B Baker; Serdar M Dursun
Journal:  Front Psychiatry       Date:  2018-10-30       Impact factor: 4.157

9.  Angiotensin II, dopamine and nitric oxide. An asymmetrical neurovisceral interaction between brain and plasma to regulate blood pressure.

Authors:  I Banegas; I Prieto; A B Segarra; M Martínez-Cañamero; M de Gasparo; M Ramírez-Sánchez
Journal:  AIMS Neurosci       Date:  2019-07-26

Review 10.  The role of nitric oxide in brain disorders: Autism spectrum disorder and other psychiatric, neurological, and neurodegenerative disorders.

Authors:  Manish Kumar Tripathi; Maryam Kartawy; Haitham Amal
Journal:  Redox Biol       Date:  2020-05-15       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.